Skip to main navigation
  • OUR COMPANY
    • Our Purpose
    • Our Leadership
    • Our Locations
  • OUR FOCUS
    • The Problem
    • Uterine Fibroids
    • Endometriosis
    • Prostate Cancer
    • Infertility
  • OUR SCIENCE
    • Pipeline
    • Relugolix Combination Therapy
    • MVT-602
  • OUR MEDICINE
  • OUR ADVOCACY
    • Forward Together
  • JOIN THE TEAM
    • Our Culture
    • Our Benefits
    • Open Positions
  • Investors & Media
    • Company Overview
    • News & Events
      • Press Releases
      • Events
      • Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
      • Analyst Coverage
    • Financials & Filings
      • SEC Filings
    • Corporate Governance
      • Board of Directors
      • Documents & Charters
      • Committee Composition
      • Expanded Access
    • Email Alerts
  • Contact Us
  • Twitter
  • LinkedIn

Press Releases

Press Releases

February 22, 2021
Myovant Sciences to Present at Upcoming Investor Conferences
February 17, 2021
Myovant Sciences and Pfizer Announce Publication in the New England Journal of Medicine of Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
February 17, 2021
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
February 16, 2021
HealthyWomen and Myovant Sciences Launch “Voices of Periods” to Fight Menstrual Stigma
February 11, 2021
Myovant Sciences Announces Corporate Updates and Financial Results for Third Quarter of Fiscal Year 2020
January 29, 2021
Myovant Sciences to Host Third Fiscal Quarter 2020 Earnings Conference Call at 8:30 a.m. Eastern Time on February 11, 2021
January 26, 2021
Myovant Sciences and Pfizer Announce Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis
January 20, 2021
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
January 5, 2021
CORRECTION -- Myovant Sciences to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 5, 2021
Myovant Sciences Announces U.S. Availability of ORGOVYX™ for the Treatment of Advanced Prostate Cancer

Pagination

  • Current page 1
  • Page 2
  • Next page next ›
  • Last page last »
Displaying 1 - 10 of 11

Toolkit

Print Page
RSS Feeds
Email Alerts
Contact
Search
  • OUR COMPANY
    • Our Purpose
    • Our Leadership
    • Our Locations
  • OUR FOCUS
    • The Problem
    • Uterine Fibroids
    • Endometriosis
    • Prostate Cancer
    • Infertility
  • OUR SCIENCE
    • Pipeline
    • Relugolix Combination Therapy
    • MVT-602
  • OUR MEDICINE
  • OUR ADVOCACY
    • Forward Together
  • JOIN THE TEAM
    • Our Culture
    • Our Benefits
    • Open Positions
  • Investors & Media
    • Company Overview
    • News & Events
    • Stock Information
    • Financials & Filings
    • Corporate Governance
    • Email Alerts
  • Contact Us
© 2021 Myovant Sciences GmbH. All rights reserved.
Terms of Use Privacy Policy Cookie Policy